Takeda Pharmaceutical has received FDA approval for three new type 2 diabetes therapies Nesina (alogliptin) and fixed-dose combinations Oseni (alogliptin and pioglitazone) and Kazano (alogliptin and metformin HCl). Takeda expects to ...
Tags: FDA, diabetes therapies, Pharmaceuticals
Furiex Pharmaceuticals said Takeda Global Research & Development Center has resubmitted New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone ...
Tags: Furiex Pharmaceuticals, NDAs, alogliptin and pioglitazone
Takeda Pharmaceutical has received a complete response letter from the US Food and Drug Administration (FDA) regarding its new drug applications (NDAs) for alogliptin and the fixed-dose combination therapy alogliptin and pioglitazone. ...
Tags: FDA, alogliptin, clinical trial program